Skip to main content
Clinical Trials/ISRCTN12572202
ISRCTN12572202
Active, not recruiting
未知

A MULTI-centre feasibility study to assess the use of 99m Tc-SestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

niversity College London0 sites150 target enrollmentMay 5, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity College London
Enrollment
150
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36693694/ (added 25/01/2023)

Registry
who.int
Start Date
May 5, 2022
End Date
August 31, 2024
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity College London

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \>18 years, and \<95 years of age
  • 2\. Any gender
  • 3\. cT1 renal tumour \>2cm identified on cross sectional imaging (CT or MRI) of unknown histological diagnosis
  • 4\. Patients undergoing tumour biopsy or surgery as part of routine care
  • 5\. Willing and able to provide informed consent.

Exclusion Criteria

  • 1\. Females who are pregnant, planning pregnancy or breastfeeding
  • 2\. Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within 3 months of study enrolment
  • 3\. Multiple comorbidities which would make trial participation difficult (e.g. burden of an additional hospital visit).
  • 4\. Allergy to 99mTc Sestamibi

Outcomes

Primary Outcomes

Not specified

Similar Trials